Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2012

Firms Ally on Diagnostic for 70,000 Pathogens

  • Affymetrix and Singapore’s PathGEN Dx inked a ‘Powered by Affymetrix (PbA) agreement, through which PathGEN will develop an in vitro pathogen diagnostic kit based on its PathGEN® PathChip microarray technology. The kit will comprise the firm’s reagents and automated software, and a contract-manufactured Affymetrix GeneChip® microarray. The firms say the final product will be able to detect over 70,000 viral and bacterial genomes from a range of human samples, as well as annotate the genomic information and identify co-infecting pathogens.

    The PbA program allows commercial players to license GeneChip® technology for the development of microarray products for a range of applications including diagnostics, forensics, animal testing, industrial testing, and food testing. “We are very pleased to have PathGEN Dx join the Affymetrix PbA program,” comments Roger Schaller Sr., director of global business development of clinical applications at Affymetrix. “This adds significantly to our PbA program in which we help partners to develop novel molecular diagnostic tests that will potentially provide solutions for directing proper treatment for patients.”

    PathGEN Dx is the first company to have been spun out of the Genome Institute of Singapore. The firm is focused on the development of diagnostic kits for infectious disease diagnostics, biosurveillance, and epidemiology. 



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »